A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies-Reference-Cited by-同舟云学术

A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies

Published:2018-05-01 Issue:5 Volume:31 Page:173-179
ISSN:1741-0126
Container-title:Protein Engineering, Design and Selection
language:en
Short-container-title:

Author:

De Luca Roberto¹^ORCID,Kachel Paul²,Kropivsek Klara³,Snijder Berend³,Manz Markus G²,Neri Dario¹

Affiliation:

1. Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Vladimir-Prelog-Weg 4, Zürich, Switzerland

2. Department of Hematology, University Hospital and University of Zurich, Rämistrasse 100, Zürich, Switzerland

3. Department of Biology, Institute of Molecular System Biology, Swiss Federal Institute of Technology (ETH Zürich), Auguste-Piccard-Hof 1, Zurich, Switzerland

Funder

ETH

Swiss National Science Foundation

ERC Advanced Grant ‘Zauberkugel’

Swiss Federal Commission for Technology and Innovation

CTI Project ‘DUAL CYTOKINE-ANTIBODY FUSIONS’

Stiftung zur Krebsbekämpfung

Publisher

Oxford University Press (OUP)

Subject

Molecular Biology,Biochemistry,Bioengineering,Biotechnology

Link

http://academic.oup.com/peds/article-pdf/31/5/173/25825666/gzy015.pdf

Reference44 articles.

1. A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

2. Tumor-Targeting Properties of Novel Antibodies Specific to the Large Isoform of Tenascin-C

3. SnapShot: Multiple Myeloma

4. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tripokin: A multi‐specific immunocytokine for cancer immunotherapy;International Journal of Cancer;2024-08-23

2. Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy;OncoTargets and Therapy;2024-08

3. Advancements and challenges in immunocytokines: A new arsenal against cancer;Acta Pharmaceutica Sinica B;2024-08

4. An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions;Antibodies;2023-04-14

5. The present and future of immunocytokines for cancer treatment;Cellular and Molecular Life Sciences;2022-09-06